| DOC |
Report |
FFO as Adjusted per share |
BEAT |
pred ~$0.44 vs. cons $0.43 |
MEDIUM |
| DOC |
Report |
Total same-store Cash Adjusted NOI growth |
BEAT |
pred ~1.2% vs. cons 0.0% |
MEDIUM |
| DOC |
Report |
Lab total occupancy |
IN-LINE |
pred ~78.3% vs. cons 78.0% |
MEDIUM |
| DOC |
Guide |
2026 FFO as Adjusted per share guidance |
BETTER |
guide ~$1.73-$1.77 vs. cons $1.74 (FY2026) |
MEDIUM |
| DOC |
Guide |
Total same-store Cash Adjusted NOI growth guidance |
BETTER |
guide ~0.0%-2.0% vs. cons 0.5% (FY2026) |
MEDIUM |
| DOC |
Guide |
Year-end Lab total occupancy commentary |
BETTER |
guide ~78.5% vs. cons 78.0% (4Q2026) |
LOW |
| DOC |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.5% |
— |
MEDIUM |
| DOC |
Return |
5-day cumulative residual |
+3.5% (FOLLOW-THROUGH) |
A ~$0.44 quarterly FFO result versus $0.43 consensus plus a ~$1.75 midpoint versus $1.74 consensus supports modest 2027 estimate upside: lab occupancy improvement and stronger same-store NOI make the beat more durable than a one-quarter timing benefit. |
MEDIUM |